- Size
- 80mg
- Purity
- 99.82%
KLOW is a four-component research blend combining BPC-157 (10 mg), TB-500 (10 mg), GHK-Cu (50 mg), and KPV (10 mg) in a single 80 mg vial. Each component occupies a different, overlapping niche in the tissue-repair literature: BPC-157 is a gastric-juice-derived pentadecapeptide studied for fibroblast migration, vascular recruitment, and growth-factor-receptor expression across tendon, ligament, and gut models.
TB-500 is a synthetic fragment of thymosin beta-4, the major actin-sequestering peptide in mammalian cells; wound models report accelerated re-epithelialisation, keratinocyte migration, and angiogenesis with thymosin beta-4 administration. GHK-Cu — the blend's largest component by mass — contributes the copper-peptide axis: collagen synthesis, balanced matrix-metalloproteinase expression, and the broad remodelling gene signature described in the copper-peptide reviews.
KPV, the C-terminal tripeptide of alpha-MSH, rounds out the blend on the inflammatory side: it retains the anti-inflammatory activity of the parent hormone without its melanotropic effects, with published work describing PepT1-mediated cellular uptake and reduced inflammatory signalling in epithelial and immune-cell models. The blend's rationale in the research literature is this complementarity — migration and vascular recruitment, actin-mediated motility, matrix remodelling, and inflammation resolution addressed by four different mechanisms in one vial.
Categorised as Skin — Copper peptides and compounds for dermal research.For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.